MXPA05008785A - Esteres de polietilen glicol activados. - Google Patents
Esteres de polietilen glicol activados.Info
- Publication number
- MXPA05008785A MXPA05008785A MXPA05008785A MXPA05008785A MXPA05008785A MX PA05008785 A MXPA05008785 A MX PA05008785A MX PA05008785 A MXPA05008785 A MX PA05008785A MX PA05008785 A MXPA05008785 A MX PA05008785A MX PA05008785 A MXPA05008785 A MX PA05008785A
- Authority
- MX
- Mexico
- Prior art keywords
- esters
- oxalate
- polyethylene glycol
- carbonate
- activated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Polyethers (AREA)
- Polyesters Or Polycarbonates (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44835403P | 2003-02-19 | 2003-02-19 | |
| PCT/IB2004/000424 WO2004074345A2 (en) | 2003-02-19 | 2004-02-13 | Carbonate esters of polyethylene glycol activated by means of oxalate esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05008785A true MXPA05008785A (es) | 2005-10-18 |
Family
ID=32908577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05008785A MXPA05008785A (es) | 2003-02-19 | 2004-02-13 | Esteres de polietilen glicol activados. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7094872B2 (https=) |
| EP (1) | EP1597299A2 (https=) |
| JP (1) | JP2006517995A (https=) |
| AR (1) | AR043216A1 (https=) |
| BR (1) | BRPI0407511A (https=) |
| CA (1) | CA2515612A1 (https=) |
| MX (1) | MXPA05008785A (https=) |
| TW (1) | TW200426155A (https=) |
| WO (1) | WO2004074345A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1259563T4 (en) | 1999-12-22 | 2016-11-21 | Nektar Therapeutics | PROCEDURE FOR PREPARING 1-BENZOTRIAZOLYL CARBONATE ESTERS OF WATER SOLUBLE POLYMERS |
| ATE371680T1 (de) | 2002-01-16 | 2007-09-15 | Biocompatibles Uk Ltd | Polymerkonjugate |
| GB0301014D0 (en) * | 2003-01-16 | 2003-02-19 | Biocompatibles Ltd | Conjugation reactions |
| ITPD20040159A1 (it) * | 2004-06-21 | 2004-09-21 | Univ Degli Studi Trieste | Derivati bifunzionali del polietilenglicole loro preparazione e uso. |
| US8133707B2 (en) * | 2006-01-17 | 2012-03-13 | Enzon Pharmaceuticals, Inc. | Methods of preparing activated polymers having alpha nitrogen groups |
| JP2007209543A (ja) * | 2006-02-09 | 2007-08-23 | Hidetoshi Tsuchida | 表面修飾アルブミンからなる固相膜および酸素吸着膜 |
| JP2009533347A (ja) | 2006-04-07 | 2009-09-17 | ネクター セラピューティックス エイエル，コーポレイション | 抗ＴＮＦα抗体の複合体 |
| EP4089133A1 (en) * | 2021-05-14 | 2022-11-16 | Johannes Gutenberg-Universität Mainz | Poly(ethylene glycol) having c1 to c3-alkyloxymethyl side chains, bioconjugates thereof, process for its preparation and its use. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| US5618697A (en) * | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| JPH07500315A (ja) * | 1991-05-10 | 1995-01-12 | セルトリックス ファーマシューティカルズ，インコーポレイテッド | 骨成長因子の標的送達 |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5650234A (en) * | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
-
2004
- 2004-02-13 EP EP04710945A patent/EP1597299A2/en not_active Withdrawn
- 2004-02-13 BR BRPI0407511-0A patent/BRPI0407511A/pt not_active IP Right Cessation
- 2004-02-13 JP JP2006502450A patent/JP2006517995A/ja not_active Withdrawn
- 2004-02-13 CA CA002515612A patent/CA2515612A1/en not_active Abandoned
- 2004-02-13 MX MXPA05008785A patent/MXPA05008785A/es not_active Application Discontinuation
- 2004-02-13 WO PCT/IB2004/000424 patent/WO2004074345A2/en not_active Ceased
- 2004-02-18 AR ARP040100501A patent/AR043216A1/es unknown
- 2004-02-18 TW TW093103934A patent/TW200426155A/zh unknown
- 2004-02-19 US US10/782,268 patent/US7094872B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7094872B2 (en) | 2006-08-22 |
| AR043216A1 (es) | 2005-07-20 |
| TW200426155A (en) | 2004-12-01 |
| CA2515612A1 (en) | 2004-09-02 |
| WO2004074345A3 (en) | 2005-01-20 |
| JP2006517995A (ja) | 2006-08-03 |
| US20040162388A1 (en) | 2004-08-19 |
| EP1597299A2 (en) | 2005-11-23 |
| BRPI0407511A (pt) | 2006-02-14 |
| WO2004074345A2 (en) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2298331A3 (en) | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins | |
| CY1119243T1 (el) | Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf | |
| AU2003228962A1 (en) | Ferritin fusion proteins for use in vaccines and other applications | |
| CY1114244T1 (el) | Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| NZ591261A (en) | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin | |
| EA200500644A1 (ru) | Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая | |
| AU4981101A (en) | Subtilisin variants | |
| BRPI0113477B8 (pt) | proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula | |
| WO2004111081A3 (en) | Antigenic peptides of sars coronavirus and uses thereof | |
| WO2002055098A3 (en) | Latency associated peptide for providing latency to pharmaceutically active proteins | |
| WO2003028757A1 (en) | Novel method of inducing antigen-specific t cells | |
| WO2004074486A3 (en) | Fusion proteins of interferon alpha muteins with improved properties | |
| DE60236796D1 (de) | Verzweigte polyalkylenglykole | |
| WO2006023665A3 (en) | Il-1 antagonist formulations | |
| MXPA05008785A (es) | Esteres de polietilen glicol activados. | |
| BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
| WO2006060021A3 (en) | Bifunctional fusion proteins containing the flt3 ligand | |
| EP1080724A4 (en) | COMPOSITIONS FOR REDUCING MTP ACTIVITY | |
| MY136546A (en) | A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component | |
| DE60236330D1 (de) | Biologisch aktive Peptide | |
| EP1557466A4 (en) | TUMORANT PROPERTIES AND USE THEREOF | |
| WO2003017938A3 (en) | Conjugates targeted to target receptors | |
| WO2003092736A3 (en) | Peptide nucleic acid conjugates with transporter peptides | |
| TW200503748A (en) | Biologically active peptide comprising tyrosyl-seryl-valine (YSV) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |